Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $2.38 in the prior trading day, CytomX Therapeutics Inc (NASDAQ: CTMX) closed at $2.38, up 0.21%. In other words, the price has increased by $0.21 from its previous closing price. On the day, 0.67 million shares were traded. CTMX stock price reached its highest trading level at $2.5 during the session, while it also had its lowest trading level at $2.38.
Ratios:
Our goal is to gain a better understanding of CTMX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.73. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.11.
Piper Sandler Upgraded its Neutral to Overweight on May 28, 2024, whereas the target price for the stock was revised from $2.25 to $3.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 16 ’25 when Ogden Christopher sold 10,614 shares for $2.69 per share. The transaction valued at 28,540 led to the insider holds 226,271 shares of the business.
Ogden Christopher sold 1,641 shares of CTMX for $4,841 on Jun 13 ’25. The Chief Financial Officer now owns 199,385 shares after completing the transaction at $2.95 per share. On Jun 16 ’25, another insider, BELVIN MARCIA, who serves as the SVP, Chief Scientific Officer of the company, sold 13,884 shares for $2.69 each. As a result, the insider received 37,334 and left with 272,252 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 375742432 and an Enterprise Value of 111273336. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.81. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.55 while its Price-to-Book (P/B) ratio in mrq is 7.68. Its current Enterprise Value per Revenue stands at 0.754 whereas that against EBITDA is 2.956.
Stock Price History:
The Beta on a monthly basis for CTMX is 2.14, which has changed by 0.6448276 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, CTMX has reached a high of $3.10, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is 3.62%, while the 200-Day Moving Average is calculated to be 92.30%.
Shares Statistics:
The stock has traded on average 5.22M shares per day over the past 3-months and 1499070 shares per day over the last 10 days, according to various share statistics. A total of 157.54M shares are outstanding, with a floating share count of 103.23M. Insiders hold about 34.47% of the company’s shares, while institutions hold 31.68% stake in the company. Shares short for CTMX as of 1749772800 were 20791019 with a Short Ratio of 4.29, compared to 1747267200 on 17729196. Therefore, it implies a Short% of Shares Outstanding of 20791019 and a Short% of Float of 13.71.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
